INITIATING COVERAGE

NVO — Novo Nordisk A/S

Global Pharmaceuticals | GLP-1 Franchise

Current Price: $40.46 (ADR, NYSE) | Market Cap: $180B | 2026-04-21

Agentic Finance Chile — Produced via Agentic AI Workflow

Executive Summary

We initiate coverage of Novo Nordisk A/S (NYSE: NVO) with a BUY rating and a 12-month target price of $61.50 per ADR, implying ~52% upside from the current $40.46 close. Our target is derived from a probability-weighted DCF (Bear 25% / Base 50% / Bull 25%) cross-checked against peer-median valuation multiples. The rating and target are outputs of the quantitative valuation — not preselected — and reflect a de-rating that has overshot fundamental deterioration.

The investment thesis rests on three pillars: (1) NVO remains the global #1 incretin franchise by revenue at ~$44B 2025E, with 44% EBITDA margin and 52% ROIC — fundamentals that have deteriorated modestly but not materially vs. the 30x-40x P/E peak valuation of mid-2024; (2) The stock has de-rated from ~32x forward P/E to 12.5x — now trading in line with pharma sector median despite superior growth and best-in-class ROIC; (3) The pipeline remains optionality-rich with near-term binary readouts (amycretin 2H 2026, MASH approval, CagriSema commercial launch) that could re-rate multiples upward, while the bear-case downside is partially priced in.

Key risk: LLY's retatrutide (Phase 3 readout 2H 2026) threatens to widen the efficacy gap in obesity. NVO's amycretin must deliver >25% weight loss in Phase 3 to neutralize this threat. We handicap this binary at roughly 50/50 in our base case.

Summary Table

Investment Thesis — Three Pillars

Pillar 1: Franchise Resilience Despite Share Loss

NVO's market share of the US branded GLP-1 class has declined from ~55% (mid-2023) to ~42% (Q4 2025) as LLY's tirzepatide (Mounjaro / Zepbound) captured incremental script share on superior efficacy. However, the underlying class is growing so rapidly (+32% YoY 2025) that NVO's absolute revenue continues to grow mid-to-high single digits. The franchise is losing share in a rising tide, not shrinking in absolute terms.

Management has responded by (a) normalizing Wegovy supply (Catalent integration closed Dec 2024; supply unrestricted since Q2 2025), (b) accelerating label expansion (MASH approval expected 2H 2026, CKD label live Nov 2024, OSA live), (c) investing in pipeline (R&D as % of revenue up from 12% to 13%+ through 2028E). These steps do not restore efficacy leadership but do stabilize revenue trajectory.

We model share stabilization at 40-45% of class volume by 2027, with continued absolute revenue growth from obesity category expansion, label-driven payer coverage improvements, and MASH/CKD franchise monetization. This is consistent with management's Feb 2026 guidance of 'mid-teens local-currency revenue growth' through 2028.

Pillar 2: De-Rating Overshoot — Mean Reversion Opportunity

NVO has experienced the largest peak-to-trough de-rating in large-cap pharma in two decades. From a June 2024 peak of ~$145 at 32x forward P/E and ~23x EV/EBITDA, the stock has declined ~72% to $40 / 12.5x / 8.5x. This compression exceeds the magnitude of earnings revisions (-15% 2026 consensus from peak) by a factor of ~3:1.

The current 8.5x EV/EBITDA is at a 55% discount to NVO's 5-year average (19x) and 10-15% discount to pharma sector median (~9.5x). The multiple implies one of two things: (a) the market believes NVO's growth converges to 0-2% permanently (inconsistent with our forecast of 6-9% mid-cycle), or (b) NVO's terminal EBITDA margin compresses to mid-30s (inconsistent with structural moat analysis: Catalent-integrated supply, SNAC oral platform, rare disease franchise stability).

We believe multiple re-rating to 10x EV/EBITDA and 16x P/E is achievable over 12-18 months as (a) amycretin Phase 3 data removes pipeline uncertainty, (b) MASH/CKD label monetization shows up in results, (c) IRA 2027 pricing impact proves manageable (consensus already prices 3-5% price erosion). At a re-rated multiple on 2027E numbers, fair value is $58-65.

Pillar 3: Pipeline Optionality — Amycretin & Label Expansion

Four pipeline events offer differentiated upside optionality:

• Amycretin (Phase 2b data 2H 2026, Phase 3 initiation 1H 2027): NVO's amylin/GLP-1 unimolecular co-agonist showed 13.1% weight loss at 12 weeks in Phase 1 (Mar 2024). If Phase 2b confirms a one-year projection of 22-25%+ weight loss, NVO regains a competitive position against LLY's retatrutide and potentially leapfrogs to class efficacy leadership.
• MASH label (ESSENCE PDUFA 2H 2026): Semaglutide demonstrated statistically significant resolution of MASH and fibrosis improvement. First-to-market GLP-1 for MASH opens a US$15B+ addressable market by 2030. Unlike obesity, MASH enjoys mandatory hepatology reimbursement (no payer gating) and can add $3-5B to revenue by 2028.
• CagriSema commercial launch (2026): Following REDEFINE-1 (22.7% weight loss) and REDEFINE-2 (15.7%) Phase 3 results, expected FDA approval 1H 2026 with launch 2H 2026. Likely positioned as premium-efficacy option for patients who plateau on Wegovy; US$3-6B peak revenue potential.
• Capital return acceleration: Board authorized DKK 20B (~US$2.9B) buyback program Feb 2026, augmenting 45%+ dividend payout. At current price, buyback alone retires ~1.6% of shares annually. Catalent capex peak behind us (2025-2026); FCF should inflect to $18-20B by 2028.

Company Overview

Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923, headquartered in Bagsværd, Denmark. It is globally the #1 diabetes franchise by revenue and the market leader in insulin (historically), GLP-1 receptor agonists (current dominant franchise), and hemophilia (via NovoSeven franchise). The company is controlled by the Novo Nordisk Foundation (77% voting rights via A-shares), providing long-term decision-making insulated from quarterly capital markets pressure.

Commercial footprint: 77 countries, 69,000+ employees. Manufacturing: 14 production sites across Denmark, US, France, Brazil, China, Iran, Russia. Post-Catalent acquisition (Dec 2024), NVO has internalized sterile fill-finish capacity in Bloomington IN, Brussels Belgium, and Anagni Italy, largely eliminating its historical supply constraint for injectable GLP-1s.

Revenue Segments (2025E)

Management & Governance

CEO Lars Fruergaard Jørgensen (since Jan 2017): Chemical engineer by training, joined NVO in 1991. Oversaw the GLP-1 franchise buildout and Catalent acquisition. Compensation package heavily equity-linked — a recent focal point of activist concern given the 2024-2025 de-rating.

CFO Karsten Munk Knudsen (since 2018): Transparent investor communicator; led financial restructuring around Catalent acquisition. Widely credited for conservative guidance framework.

Chair Helge Lund (since Mar 2023): Former BG Group CEO, well-regarded for shareholder-return discipline. Board composition includes representatives of the Novo Nordisk Foundation, providing long-term-oriented governance.

Ownership: Novo Nordisk Foundation (via Novo Holdings) holds 28.1% economic interest and ~77% voting rights via A-shares. Public float (B-shares) 72%, with ~54% held by institutional investors globally. The Foundation structure is both a governance strength (long-term focus) and an M&A constraint (strategic M&A must be approved by Foundation).

Financial Analysis

Historical Financial Performance (2023-2025)

Note: Revenues translated from DKK to USD at average annual rates (6.85 2023, 7.00 2024, 6.95 2025). Catalent acquisition closed Dec 2024; 2025 reflects first full year of impact on D&A ($3B vs. $1.5B prior) and leverage.

Forward Projections (2026-2030E)

Valuation

DCF — Probability-Weighted Target $61.50

Our primary valuation methodology is a probability-weighted DCF with WACC of 8.62% (Base), symmetric Bull/Bear Ke spreads (±125bps), terminal growth 2.5%, exit EV/EBITDA 11.0x. Ke derives from CAPM directly (Rf 4.2% + Beta 0.90 × ERP 5.5% = 9.15%) without quality adjustment. Scenario weights: Bear 25%, Base 50%, Bull 25%.

Bear scenario assumes retatrutide success + orforglipron commoditization lead to 2-4% revenue growth and 440bps margin compression. Bull assumes amycretin delivers >25% efficacy, MASH ramps strongly, and share stabilizes — supporting 8-13% revenue growth and 515bps terminal EBITDA margin. Base is the central path of 5-9% growth and 47.5% terminal margin.

Comps — Cross-Check

Pharma peer-set median NTM EV/EBITDA is 9.5x; P/E 13.0x. Applying peer-median to NVO 2026E EBITDA ($23.3B) yields implied ADR price of $54-56. Applying 75th percentile (a partial restoration of NVO's historical premium to peers, ~30%) implies $68-75. The comps-derived fair value range ($55-70) brackets the DCF-weighted $61.50 target.

We anchor to the DCF target of $61.50, which is within the $55-70 range supported by multiples-based cross-check.

Competitive Landscape & Disruptive Threat Assessment

Per coverage policy, we explicitly evaluate each material disruptive threat with scale, S-curve trajectory, evidence of materiality, trigger events, and NVO's positioning. Nothing is dismissed without justification.

Threat 1: LLY Retatrutide (Triple Agonist)

• Current scale: Zero revenue (pre-commercial). Phase 3 TRIUMPH program ongoing, obesity readout expected 2H 2026.
• S-curve trajectory: Phase 2 data showed 24.2% mean weight loss at 48 weeks — ~5-7pp beyond tirzepatide and ~10pp beyond semaglutide. If Phase 3 confirms with manageable tolerability, retatrutide takes class leadership and accelerates NVO share loss through 2028-2029.
• Why it's material: At 25%+ weight loss, GLP-1s approach bariatric surgery efficacy (~30%), at which point payer and prescriber preference concentrates on the highest-efficacy option available.
• Trigger events: (1) Retatrutide Phase 3 readout 2H 2026 — if efficacy ≥22% and GI AE discontinuation <15%, bear case activates; (2) NVO amycretin Phase 2b data 2H 2026 (expected) — if ≥20% at 64 weeks with comparable tolerability, neutralizes retatrutide lead.
• NVO positioning: CagriSema (22.7% weight loss) and amycretin are the defensive responses. Commercial launch 2026; Phase 3 data 2027-2028. Risk-adjusted outcome supports our Base case.

Threat 2: Oral Small-Molecule GLP-1s (Orforglipron class)

• Current scale: Rybelsus (NVO oral peptide) ~$2.4B annually. LLY orforglipron Phase 3 readouts expected Q4 2025 / Q1 2026. PFE danuglipron discontinued 2024; AZD5004 (AZN) and aleniglipron (GPCR) in mid-stage.
• S-curve trajectory: Oral small molecules eliminate sterile fill-finish costs; unit economics potentially 80% lower. If efficacy parity (~15% weight loss), oral reshapes mass-market and emerging-market access.
• Why it's material: 40% of eligible patients decline injectables; orforglipron addresses this population and enables primary-care prescribing patterns. Manufacturing economics undercut injectables across price-sensitive markets.
• Trigger events: (1) Orforglipron Phase 3 efficacy ≥14% + acceptable tolerability; (2) NVO oral amycretin / high-dose Rybelsus differentiation; (3) Biosimilar timelines (2033+).
• NVO positioning: Rybelsus at-market + oral amycretin pipeline + SNAC absorption platform. Competitive but not leading. Partial offset.

Threat 3: Biosimilar Semaglutide

• Current scale: No approved biosimilars. Composition-of-matter patent expires 2031 (EU) / 2033 (US with pediatric extensions).
• S-curve trajectory: Peptide biosimilars have historically taken 3-5 years post-LOE to achieve 40-60% price erosion. Slower than small-molecule generics.
• Why it's manageable (for now): Catalent supply capture + SNAC formulation patents (to 2036+) + pipeline succession limit terminal-value impact. No biosimilar developer has initiated Phase 3 BE studies visible in public filings as of Apr 2026.
• Trigger events: First biosimilar semaglutide Phase 3 initiation; patent challenge on SNAC formulation; compounding reform.
• NVO positioning: Strong. Manufacturing moat + succession franchise (amycretin, CagriSema) pre-LOE.

Threat 4: Compounded Semaglutide

• Current scale: Est. 2-3M US patients on compounded semaglutide (telehealth channels Hims, Ro, Henry Meds) — ~$3-5B in sales leakage from branded 2024.
• S-curve trajectory: FDA removed Wegovy from shortage list Feb 2025, theoretically ending 503B compounding. 503A personalized compounding continues.
• Why it persists: Telehealth platforms use 'personalized formulations' argument; enforcement is slow.
• Trigger events: FDA enforcement action; state-level AOMs access mandates expanding branded Rx coverage; consolidation of telehealth into legitimate prescribing channels.
• NVO positioning: Active litigation; new patient onboarding to branded improving with supply normalization. Headwind but not existential.

Threat 5: Weight-Loss Alternatives (Surgical / Device)

• Current scale: US bariatric surgery ~256,000/yr (flat); endoscopic/device-based declining.
• Why not a material threat: Direction is GLP-1 → surgery substitution, not reverse. GLP-1 discontinuation weight regain is known but hasn't triggered 'surgery renaissance' in 2024-2025 data.
• Trigger events: Long-term STEP-5 follow-up showing maintenance failure rates >30% at 5 years.

Overall Disruption Conclusion

The most material disruptive threat to NVO is LLY's retatrutide. Our Base case handicaps retatrutide success at ~60% probability (Phase 3 confirming Phase 2) with magnitude of share impact moderated by amycretin defense (60% probability of ≥20% Phase 2b). The Bear scenario activates only if both events go against NVO — joint probability ~25%. This is reflected in our probability-weighted DCF.

We note that while the market is currently priced for a worse-than-Bear outcome on P/E (12.5x vs. Bear-case fair multiple ~11x), the underlying fundamentals do not yet justify that pricing. This is the source of the upside.

Risks

Technology Disruption Risk

Reference: see 'Disruptive Threat Assessment' above. The primary vector is retatrutide (LLY) Phase 3 success. Secondary vector is orforglipron commoditization of oral channel. Amycretin Phase 2b (2H 2026) is the key mitigating catalyst.

Pricing & Reimbursement Risk

IRA Medicare negotiation for Ozempic/Rybelsus/Wegovy (effective Jan 2027): consensus embeds ~30% net discount on negotiated volumes. Broader PBM rebate pressure continues (formulary exclusions, prior auth). Most-favored-nation pricing under Trump administration is a tail risk. Full implementation would reduce 2027-2028 revenue by US$3-5B below our Base case.

Pipeline Execution Risk

Amycretin Phase 2b (late 2026) is the single most important catalyst. If efficacy disappoints (<20% weight loss), the bull thesis evaporates. CagriSema commercial launch execution 2026-2027 also material.

Share Concentration / Foundation Risk

Novo Nordisk Foundation holds ~77% voting rights. This structure precludes hostile M&A activity but also limits strategic optionality. The Foundation has historically been shareholder-friendly but governance changes remain a possibility in long-term scenarios.

Currency & Geographic Exposure

Approximately 60% of revenue is USD-denominated (US market); 20% EUR; 10% DKK/other European; 10% other. Reporting currency is DKK; ADR quoted in USD. DKK-to-USD fluctuations affect reported results but are mostly a translation rather than economic effect.

Regulatory / Safety Risk

Ongoing real-world safety surveillance for gastroparesis, suicidality signals, and thyroid C-cell tumor (black-box carryover). Any major label change would materially impact franchise. EMA and FDA reviews have been supportive thus far.

Debt & Capital Allocation Risk

Post-Catalent net debt/EBITDA of 0.8x is manageable but limits optionality. Capital allocation priorities are (1) Catalent capex completion, (2) dividend maintenance, (3) buyback acceleration. Mismanagement of these priorities could erode investor confidence.

Catalysts (12-month)

Target Price Derivation

Target price methodology: probability-weighted DCF cross-checked against peer multiples. Rating derived per pipeline rule:

• BUY: implied upside >15% from current price
• HOLD: implied range -5% to +15%
• SELL: implied downside >5%

Probability-weighted implied price: $61.58. Rounded down to nearest $0.50 per coverage policy (no rounding up) = $61.50 target. Implied upside = +52.0%. Rating: BUY.

Historical Re-rating Path to $61.50

At $61.50, NVO trades at 16x 2027E P/E, 10x 2027E EV/EBITDA, and 3.5x EV/Revenue. This is a ~15-25% premium to current pharma median multiples — a partial restoration of NVO's historical premium (40% vs. peers over 2018-2023) and consistent with franchises of similar growth/margin profile (e.g., LLY at 34x, MRK at 12x, ABBV at 15x). We view this as achievable given the pipeline catalysts over 12-18 months.

Disclaimer

This report was produced by an agentic AI workflow (Agentic Finance Chile) for research and educational purposes only. All financial data is sourced from public company filings, Bloomberg, FactSet consensus, and industry sources (IQVIA, EvaluatePharma) current to April 2026. Data may contain inaccuracies or errors introduced during automation.

The analysis reflects probabilistic views on clinical, regulatory, and commercial outcomes. Actual results may differ materially. The author holds no position in NVO, LLY, or any related security at time of publication. This is not investment advice. Readers should conduct their own due diligence and consult licensed financial advisors before making investment decisions.

Agentic Finance Chile — Apr 2026